GCG104

GCG104 is a novel, long-acting peptide analogue of glucagon that functions as a highly specific and potent agonist of the glucagon receptor (GCGR). Developed by Novo Nordisk, it is primarily utilized in research to investigate the physiological and metabolic consequences of chronic glucagon receptor activation. Studies in murine models have demonstrated that GCG104 induces significant weight loss through direct signaling at the glucagon receptor in the liver, rather than through central nervous system pathways. Its high selectivity for the GCGR over the GLP-1 receptor makes it a valuable tool for isolating glucagon-specific biological effects on energy expenditure, lipid metabolism, and glucose homeostasis, supporting the development of next-generation metabolic syndrome pharmacotherapies.

Other names

glucagon analogue